EMA to mull Tysabri-naive Gilenya PML case
This article was originally published in Scrip
Executive Summary
A confirmed case of the rare, serious brain condition progressive multifocal leukoencephalopathy (PML) in a multiple sclerosis patient treated with Novartis's Gilenya (fingolimod) without prior treatment with Biogen's Tysabri (natalizumab) is to be considered by the European Medicine Agency's CHMP meeting this week.